Dragonfly Therapeutics, Inc. announced that Celgene Switzerland LLC, an affiliate of Celgene Corporation, a leading global biopharmaceutical company, and a number of family office investors including Disney family members and the Duke of Bedford, have completed a new round of investment in Dragonfly.

"This investment by Celgene, Disney family members and the Duke of Bedford, reflects their confidence in our mission to revolutionize cancer treatment by inventing therapies that harness the body's immune system for vastly improved patient outcomes," said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. "We appreciate the demonstrated confidence in the future of Dragonfly, and are eager to accelerate our work to develop potential new immuno-oncology treatment options for patients."

About Dragonfly

Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer.